Ryan Deschner
Stock Analyst at Raymond James
(2.39)
# 2,477
Out of 4,761 analysts
8
Total ratings
71.43%
Success rate
6.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $5.06 | +156.92% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $11.24 | +149.11% | 3 | Jan 14, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Outperform | $9 | $4.60 | +95.65% | 1 | Aug 30, 2024 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $16.12 | +67.55% | 2 | Aug 19, 2024 | |
| OMGA Omega Therapeutics | Initiates: Outperform | $12 | $0.16 | +7,404.69% | 1 | Jun 18, 2024 |
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $5.06
Upside: +156.92%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $11.24
Upside: +149.11%
Trevi Therapeutics
Aug 30, 2024
Initiates: Outperform
Price Target: $9
Current: $4.60
Upside: +95.65%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $16.12
Upside: +67.55%
Omega Therapeutics
Jun 18, 2024
Initiates: Outperform
Price Target: $12
Current: $0.16
Upside: +7,404.69%